Showing 4381-4390 of 8581 results for "".
- Foods High in Sugar and Fat Disrupt the Gut Microbiome and Trigger Psoriasis Flareshttps://practicaldermatology.com/news/foods-high-in-sugar-and-fat-disrupt-the-gut-microbiome-and-trigger-psoriasis-flares/2460846/Diets rich in sugar and fat may lead to an imbalance in the gut’s microbial culture and contribute to inflammatory skin diseases such as psoriasis, according to a new study in the Journal o
- More than Half of US Cosmetics May Contain "Forever Chemicals"https://practicaldermatology.com/news/more-than-half-of-us-cosmetics-may-contain-pfas/2460842/More than half of the make-up products sold in the United States and Canada may contain toxic chemicals, a new study suggests. When researchers out of the University of Notre Dame tested 231 commonly used cosme
- Research Brief: Personalized Bacteriotherapy May Improve Skin Microbiome and Symptoms in ADhttps://practicaldermatology.com/news/research-brief-personalized-bacteriotherapy-may-improve-skin-microbiome-and-symptoms-in-ad/2460841/Bacteriotherapy with an autologous strain of bacteria may safely improve S. aureus colonization in the microbiome of patients with atopic dermatitis (AD) and improve disease severity, a
- Merz Aesthetics Launches New Online Aesthetics Education Platformhttps://practicaldermatology.com/news/merz-aesthetics-launches-new-online-aesthetics-education-platform/2460830/Merz Aesthetics is launching Merz Aesthetics Medical Forum, an online medical aesthetics education platform for health care professionals around the world. Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthe
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchangehttps://practicaldermatology.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange/2460824/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- Parents Magazine Announces Winners of Best Skin Care for Kids 2021https://practicaldermatology.com/news/parents-magazine-announces-winners-of-best-skin-care-for-kids-2021/2460823/Meredith Corporation's Parents magazine released this year's Best Skin Care for Kids. Parents experts thoroughly tested nearly 300 formulas of parent recommendations, brand best-sellers, and new releases for skin and hair with 55 families. A total of 30 products that are a
- NPF COVID-19 Task Force: Masks, Social Distancing Still Important for Many Vaccinated Psoriasis Patientshttps://practicaldermatology.com/news/npf-covid-19-task-force-masks-social-distancing-still-important-for-many-vaccinated-psoriasis-patients/2460818/In mid-May 2021, the Centers for Disease Control and Prevention (CDC) released
- Bliss Becomes First Mass & Drug Skincare Brand to Receive B Corp Certificationhttps://practicaldermatology.com/news/bliss-becomes-first-mass-drug-skincare-brand-to-receive-b-corp-certification/2460814/Bliss is the first-ever skincare brand sold at mass and drug to achieve B Corp Certification. This certification confirms that Bliss meets the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance pr
- Meet PDO Max's New Executive Hireshttps://practicaldermatology.com/news/meet-pdo-maxs-new-executive-hires/2460810/Dina BenDavid is the new Director of Training and Clinical Development at PDO Max. BenDavid is a board-certified nurse practitioner, holds both a Master's and Doctoral degrees, and is a professor of nursing and clinical trainer in medical aesthetics. She is founder and owner of
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas